{"title":"Prevalence of probable central sensitization defined using the Central Sensitization Inventory and its association with clinical outcomes in axial spondyloarthritis: a systematic review and meta-analysis","authors":"Salieva Rana, Aziza Seitova, Keneshbek Ismanov, Bakhtierova Mushtarii, Umurzakova Gavkharoi Islamovna, Feruzakhan Tazhibaeva, Mamasaidov Abdimutalib","doi":"10.1016/j.reuma.2026.502293","DOIUrl":"10.1016/j.reuma.2026.502293","url":null,"abstract":"<div><div>This study aimed to estimate the pooled prevalence of central sensitization (CS) features defined by the Central Sensitization Inventory (CSI<!--> <!-->≥<!--> <!-->40) and quantify its association with disease activity, pain, quality of life, and physical function in axial spondyloarthritis (axSpA). Systematic searches were conducted in PubMed, Scopus, and Web of Science from inception to April 2026. Observational studies reporting CSI scores and patient-reported outcomes in axSpA were included. Random-effects meta-analyses pooled prevalence and standardized mean differences (SMDs) for BASDAI, pain VAS, ASQoL, BASFI, and ASDAS-CRP, comparing CSI<!--> <!-->≥<!--> <!-->40 versus CSI<!--> <!--><<!--> <!-->40 patients. Certainty was assessed using GRADE. Seventeen studies (1278 patients) were included. The pooled prevalence of CSI-defined probable CS (score<!--> <!-->≥<!--> <!-->40) was 48.5% (95% CI: 44.1–52.8%; <em>I</em><sup>2</sup> <!-->=<!--> <!-->55%). Compared with CSI<!--> <!--><<!--> <!-->40 patients, those with CSI<!--> <!-->≥<!--> <!-->40 had significantly worse outcomes: BASDAI (SMD<!--> <!-->=<!--> <!-->1.76; 95% CI: 1.21–2.31; <em>I</em><sup>2</sup> <!-->=<!--> <!-->88%), pain VAS (SMD<!--> <!-->=<!--> <!-->1.32; 95% CI: 0.91–1.73; <em>I</em><sup>2</sup> <!-->=<!--> <!-->56%), ASQoL (SMD<!--> <!-->=<!--> <!-->1.88; 95% CI: 1.18–2.57; <em>I</em><sup>2</sup> <!-->=<!--> <!-->90%), BASFI (SMD<!--> <!-->=<!--> <!-->1.35; 95% CI: 1.10–1.60; <em>I</em><sup>2</sup> <!-->=<!--> <!-->77%), and ASDAS-CRP (SMD<!--> <!-->=<!--> <!-->1.02; 95% CI: 0.84–1.20; <em>I</em><sup>2</sup> <!-->=<!--> <!-->0%); all with <em>p</em> <!--><<!--> <!-->0.0001. Absolute differences on original scales were approximately 3 BASDAI points (0–10), 2–3<!--> <!-->cm VAS (0–10), 6–8 ASQoL points (0–18), and 1.5–2 BASFI points (0–10). GRADE certainty was low for prevalence and very low for most outcomes due to observational designs and heterogeneity. CSI-defined probable CS features affect nearly one in two axSpA patients and are associated with large, clinically meaningful adverse effects across multiple patient-centered outcomes. These findings suggest that screening for CSI-defined probable CS features may be clinically useful in selected patients, particularly those with persistently high symptom burden despite controlled inflammation.</div><div>PROSPERO registration: CRD420261380153.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 9","pages":"Article 502293"},"PeriodicalIF":1.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149314374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Reumatologia ClinicaPub Date : 2026-11-01Epub Date: 2026-09-02DOI: 10.1016/j.reuma.2026.502277
Stacy Jocelyn Echeverria Quintana, Catarina Cé Bella Cruz, Luiza Mousquer Leal, Caio Cesar Silva de Castro
{"title":"Familial linear scleroderma: A case for reassessment and a potential first report from Brazil","authors":"Stacy Jocelyn Echeverria Quintana, Catarina Cé Bella Cruz, Luiza Mousquer Leal, Caio Cesar Silva de Castro","doi":"10.1016/j.reuma.2026.502277","DOIUrl":"10.1016/j.reuma.2026.502277","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 9","pages":"Article 502277"},"PeriodicalIF":1.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149314376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Reumatologia ClinicaPub Date : 2026-11-01Epub Date: 2026-09-11DOI: 10.1016/j.reuma.2026.502290
Denisse Ovejero, Maylen Cingolani, Diego Faus, Lucia Navarro Redondo, Constanza Balacco, Juan Pablo Ford
{"title":"Functional and quality of life characteristics in children with juvenile dermatomyositis during their first outpatient consultation: A descriptive, retrospective study","authors":"Denisse Ovejero, Maylen Cingolani, Diego Faus, Lucia Navarro Redondo, Constanza Balacco, Juan Pablo Ford","doi":"10.1016/j.reuma.2026.502290","DOIUrl":"10.1016/j.reuma.2026.502290","url":null,"abstract":"<div><h3>Background and objective</h3><div>To describe the functional capacity, muscle strength, clinical-demographic characteristics, and quality of life and respiratory function of children diagnosed with juvenile dermatomyositis (JDM) during their initial outpatient consultation at the Physical Therapy Unit (PTU).</div></div><div><h3>Materials and methods</h3><div>A descriptive, retrospective, and cross-sectional study. The study included 51 subjects under 16 years of age diagnosed with JDM, evaluated between 2018 and 2024, who had completed the full PTU evaluation protocol.</div></div><div><h3>Results</h3><div>Fifty-one children with a diagnosis of JDM were analyzed; the median age was 9.06 years (IQR: 6–12). The Disease Activity Score (DAS) showed a median of 9 (IQR: 5–14). The median Childhood Health Assessment Questionnaire (C-HAQ) score was 0.875 (IQR: 0.25–1.75). The Childhood Myositis Assessment Scale (CMAS) presented a median of 34 (IQR: 21–46). Manual Muscle Testing (MMT) reported a median of 55 (IQR: 44–71). The median Timed Up and Go (TUG) test was 6.66<!--> <!-->s (IQR: 6.11–8.06). Of the subjects, 56.86% (29 subjects) were able to complete the 6-Minute Walk Test (6MWT), reporting a median distance of 345<!--> <!-->m (IQR: 292.5–397.5). The Pediatric Quality of Life Inventory (PedsQL) for children and caregivers showed medians of 56.98 (IQR: 41.30–87.75) and 60.71 (IQR: 45.40–84.75), respectively.</div></div><div><h3>Discussion and conclusions</h3><div>Children with JDM presented moderate impairment of functional capacity, endurance, strength, and cough efficacy during the initial evaluation. The most affected muscle groups were the neck flexors, hip flexors and hip extensors. The majority of subjects exhibited muscular and cutaneous inflammatory activity. No relevant differences were found between the quality-of-life assessments of the children and their families.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 9","pages":"Article 502290"},"PeriodicalIF":1.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149314297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Reumatologia ClinicaPub Date : 2026-11-01Epub Date: 2026-10-02DOI: 10.1016/j.reuma.2026.502285
Noé Brito García, Petra Díaz del Campo Fontecha, Victoria Navarro-Compán, Raquel Almodóvar Gonzalez, Mireia Moreno, Clementina López-Medina, María José Moreno Martínez, Luis Linares Ferrando, Aythami de Armas-Castellano, Manuel José Moreno Ramos
{"title":"Uso actual de la resonancia magnética en el diagnóstico y seguimiento de la espondiloartritis axial en España: perspectiva del reumatólogo, radiólogo y paciente en un estudio cualitativo","authors":"Noé Brito García, Petra Díaz del Campo Fontecha, Victoria Navarro-Compán, Raquel Almodóvar Gonzalez, Mireia Moreno, Clementina López-Medina, María José Moreno Martínez, Luis Linares Ferrando, Aythami de Armas-Castellano, Manuel José Moreno Ramos","doi":"10.1016/j.reuma.2026.502285","DOIUrl":"10.1016/j.reuma.2026.502285","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>Axial spondyloarthritis is a chronic inflammatory arthritis that affects the musculoskeletal system. Magnetic resonance imaging (MRI) is a technique with both advantages and disadvantages, what leads to inconsistent implementation and use across different healthcare areas. The aim of this study was to assess the current status of the use of spinal and sacroiliac MRI in the diagnosis, management, and follow-up of axial spondyloarthritis by rheumatologists in the Spanish healthcare system. Additionally, the study explored the preferences, opinions and needs of rheumatologists, as well as those of radiologists, and patient.</div></div><div><h3>Methods</h3><div>A qualitative approach was used, consisting of five focus groups with 34 participants and three in-depth individual interviews with a purposive sample that included 24 rheumatologists, six radiologists, and seven patients. Transcripts of the recordings were analysed using a constant comparison method, followed by thematic analysis.</div></div><div><h3>Results</h3><div>Based on the participants’ experiences, six thematic areas were identified: 1) diagnosis; 2) management and follow-up; 3) healthcare decisions; 4) variability in prescribing; 5) private healthcare; 6) training and communication needs. In general, there was agreement between the opinions and attitudes expressed by the participating rheumatologists and those of the participating radiologists.</div></div><div><h3>Conclusions</h3><div>The study provides a roadmap of issues to be addressed to improve patient care, primarily: inter-centre differences in access to MRI, difficulties with radiology reports from private practice, and the need for specific training and interdisciplinary communication.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 9","pages":"Article 502285"},"PeriodicalIF":1.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149314375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Reumatologia ClinicaPub Date : 2026-11-01Epub Date: 2026-08-11DOI: 10.1016/j.reuma.2026.502276
Eliezer Emmanuel Preciado-Gocobachi, Karla Sofia Ortega-Landa, Alan Fernando Ibarra-Valenzuela, Manuel Alberto Antonio Palma-Palacios
{"title":"Dermatomiositis como entidad paraneoplásica asociada a cáncer tiroideo: Revisión sistemática","authors":"Eliezer Emmanuel Preciado-Gocobachi, Karla Sofia Ortega-Landa, Alan Fernando Ibarra-Valenzuela, Manuel Alberto Antonio Palma-Palacios","doi":"10.1016/j.reuma.2026.502276","DOIUrl":"10.1016/j.reuma.2026.502276","url":null,"abstract":"<div><h3>Background</h3><div>Dermatomyositis (DM) is a rare autoimmune disease that affects both skin and muscle tissue. In some patients, it can serve as a paraneoplastic signal of an underlying malignancy. While its link to lung, ovarian, and gastrointestinal tumors is well recognized, its association with thyroid cancer remains scarcely explored.</div></div><div><h3>Objective</h3><div>This review aimed to summarize and analyze the available clinical evidence on the coexistence of DM and thyroid cancer.</div></div><div><h3>Methods</h3><div>A systematic search was performed in PubMed and Scopus from January 2000 to September 2025, following PRISMA guidelines. Eligible studies included clinical reports, case series, and observational analyses that documented a temporal or clinical relationship between both conditions. An exploratory retrospective assessment of the applicability of the 2017 ACR/EULAR criteria was also performed.</div></div><div><h3>Results</h3><div>Nine studies met the inclusion criteria. Most patients were women with an average age of 48 years. Papillary thyroid carcinoma was the most common histological subtype. The classic form of DM was predominant, and Gottron's papules along with the heliotrope rash were the most frequent cutaneous findings. Clinical improvement was commonly observed after treatment of the thyroid malignancy. The serological profile was heterogeneous and incomplete; two patients were anti-Jo-1 positive, one was anti-MDA5 positive, and one was anti-Ro52 positive.</div></div><div><h3>Conclusions</h3><div>These findings reinforce the importance of considering thyroid cancer among the possible paraneoplastic causes of dermatomyositis. Early detection of characteristic cutaneous signs may be key to identifying an underlying tumor at initial stages and improving patient prognosis.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 9","pages":"Article 502276"},"PeriodicalIF":1.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149314288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Reumatologia ClinicaPub Date : 2026-11-01Epub Date: 2026-07-31DOI: 10.1016/j.reuma.2026.502272
Natalia de la Torre-Rubio, Carolina Merino-Argumánez, Mercedes Hospital-Gil, Gastón Roustan-Gullón, Jesús Sanz-Sanz, José Luis Andreu-Sánchez
{"title":"Real-world data of the PURE-4 scale for diagnosis of psoriatic arthritis in patients with psoriasis","authors":"Natalia de la Torre-Rubio, Carolina Merino-Argumánez, Mercedes Hospital-Gil, Gastón Roustan-Gullón, Jesús Sanz-Sanz, José Luis Andreu-Sánchez","doi":"10.1016/j.reuma.2026.502272","DOIUrl":"10.1016/j.reuma.2026.502272","url":null,"abstract":"<div><h3>Background and objective</h3><div>Approximately 15% of patients with psoriasis followed by dermatologists have undiagnosed psoriatic arthritis (PsA). The progression rate of PsA is significantly higher in patients with established disease of more than two years’ duration. Therefore, screening tests for early diagnosis are crucial to prevent joint damage. Our study aims to evaluate the usefulness of the PURE-4 scale in real-world clinical practice for identifying patients with psoriatic arthritis (PsA) among individuals with psoriasis.</div></div><div><h3>Patients and methods</h3><div>Retrospective descriptive study of conducted between January 2021 and December 2023.</div></div><div><h3>Results and discussion</h3><div>A total of 60 patients with a prior diagnosis of psoriasis were referred by the Dermatology Department for suspected PsA based on the PURE-4 scale. PsA was diagnosed in 34% of patients following rheumatologic evaluation. A PURE-4 score<!--> <!-->≥<!--> <!-->2 or the presence of dactylitis alone appears to enhance the sensitivity and specificity of the PURE-4 scale.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 9","pages":"Article 502272"},"PeriodicalIF":1.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149314378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Reumatologia ClinicaPub Date : 2026-11-01Epub Date: 2026-09-24DOI: 10.1016/j.reuma.2026.502280
José M. Lou-Bonafonte, Cilia Peralta-Ginés, Javier Tenas-Gonzalvo, Blanca García-Magallón, Martín Laclaustra, Rosa Roselló
{"title":"Pharmacological treatment intensity score for rheumatoid arthritis patients (PTIS-RA_1.3)","authors":"José M. Lou-Bonafonte, Cilia Peralta-Ginés, Javier Tenas-Gonzalvo, Blanca García-Magallón, Martín Laclaustra, Rosa Roselló","doi":"10.1016/j.reuma.2026.502280","DOIUrl":"10.1016/j.reuma.2026.502280","url":null,"abstract":"<div><h3>Introduction</h3><div>Research into complementary treatments for rheumatoid arthritis (RA) is expanding. These adjuvant therapies are typically administered alongside conventional treatments, including csDMARDs, bDMARDs and tsDMARDs. Monitoring pharmacological changes is crucial to discern whether clinical improvement is due to adjuvant intervention or medication adjustments. This paper presents a tool (PTIS-RA_1.3) that converts RA pharmacological treatment into a numerical value, reflecting treatment intensity based on drug type and dosage.</div></div><div><h3>Methods</h3><div>Each drug is assigned a score based on its pharmacological class and administered dose, strictly aligned with EULAR recommendations. The scoring system was developed using consensus methodology inspired by the Delphi method.</div></div><div><h3>Results</h3><div>To illustrate the utility of the score, we present its implementation in the AIDE-RAP trial (<span><span>NCT05254223</span><svg><path></path></svg></span>). The tool successfully quantified treatment intensity and modifications over a 12-month period, as shown in the illustrative cases.</div></div><div><h3>Conclusions</h3><div>PTIS-RA_1.3 is a novel system that transforms qualitative medication data into a quantitative variable, facilitating statistical analysis and graphical representation. Furthermore, it serves as an indirect measure of disease aggressiveness by reflecting the therapeutic burden required to maintain clinical control.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 9","pages":"Article 502280"},"PeriodicalIF":1.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149314379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Reumatologia ClinicaPub Date : 2026-11-01Epub Date: 2026-10-09DOI: 10.1016/j.reuma.2026.502219
Laura Álvarez Ortiz, Manuela Sianes Fernández, Ricardo Juan Gil Vélez, Clara Aguilera Cros
{"title":"Sarcoidosis ósea con presentación pseudotumoral y progresión multifocal en la mano","authors":"Laura Álvarez Ortiz, Manuela Sianes Fernández, Ricardo Juan Gil Vélez, Clara Aguilera Cros","doi":"10.1016/j.reuma.2026.502219","DOIUrl":"10.1016/j.reuma.2026.502219","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 9","pages":"Article 502219"},"PeriodicalIF":1.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149313766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Reumatologia ClinicaPub Date : 2026-11-01Epub Date: 2026-08-14DOI: 10.1016/j.reuma.2026.502247
María Martín Ampuero, Claudia Beatriz Pérez González, María Elena Batlle López, Manuel Ruíz Muñoz
{"title":"Pericarditis cálcica asociada a esclerosis sistémica: una manifestación excepcional","authors":"María Martín Ampuero, Claudia Beatriz Pérez González, María Elena Batlle López, Manuel Ruíz Muñoz","doi":"10.1016/j.reuma.2026.502247","DOIUrl":"10.1016/j.reuma.2026.502247","url":null,"abstract":"<div><div>We report the case of a woman with diffuse systemic sclerosis and severe universal calcinosis who developed calcific pericardial effusion with early signs of constriction. This case highlights an extraordinarily rare manifestation with only nine cases reported in the medical literature to date.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 9","pages":"Article 502247"},"PeriodicalIF":1.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149313765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Anti-signal recognition particle (anti-SRP) antibodies in idiopathic inflammatory myopathy: A descriptive multicenter cross-sectional study from the Myositis Study Group of the Argentine Society of Rheumatology","authors":"Benítez Cristian Alejandro, Alfaro María Agustina, Gómez Graciela, Costi Carolina, Granel Amelia, Wernicke Verónica, Pisoni Cecilia, Cosatti Micaela, López Ignacio, Medina Gustavo, Gamba María Julieta, Peón Claudia, Yampa Vedia Yhanderin, Huici Rojas Arisai Graciela, García Carrasco Marina, Aciar Mariana, Gómez Ramiro Adrián, Kisluk Boris","doi":"10.1016/j.reuma.2026.502281","DOIUrl":"10.1016/j.reuma.2026.502281","url":null,"abstract":"<div><h3>Introduction</h3><div>Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases. Anti-signal recognition particle (anti-SRP) antibodies are present in approximately 5% of IIM and define a phenotype with severe proximal weakness and a rapidly progressive course. Data on Latin American cohorts are scarce.</div></div><div><h3>Patients and methods</h3><div>Descriptive, multicenter, cross-sectional study. Patients with anti-SRP-positive IIM fulfilling the 2017 EULAR/ACR criteria were included from the registry of the Myositis Study Group of the Argentine Society of Rheumatology (GESAR). Demographic, clinical, laboratory, and treatment data were collected. Continuous variables are reported as median and interquartile range (IQR); categorical variables as frequencies and percentages.</div></div><div><h3>Results</h3><div>Of 363 patients with IIM, 17 (4.7%) were anti-SRP positive; 88.2% were women, median age 56 years (IQR 49–69), median diagnostic delay 6 months (IQR 1–18). Immune-mediated necrotizing myopathy was the most frequent classification (64.7%). Muscle weakness was documented in 56.3%, dysphagia in 50.0%, articular involvement in 25.0%, respiratory muscle weakness in 17.6%, and interstitial lung disease in 12.5% (all non-specific interstitial pneumonia). No cardiac involvement was reported. Creatine kinase was elevated in 66.7% of patients with available measurements; no additional myositis-specific autoantibodies were detected. Treatments included glucocorticoids (88.2%), methotrexate (47.1%), azathioprine (35.3%), rituximab (29.4%), and intravenous immunoglobulin (23.5%). Hospitalization due to myositis was required in 52.9%.</div></div><div><h3>Conclusions</h3><div>In this Argentine multicenter cohort, anti-SRP-positive IIM was characterized by severe proximal weakness, frequent dysphagia, and a high hospitalization rate. The use of rituximab and intravenous immunoglobulin in nearly one-third of patients reflects the need for treatment-intensive approaches.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 9","pages":"Article 502281"},"PeriodicalIF":1.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149314377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}